Case Report
Reduction in tumor grade and Ki-67 in postmenopausal patient with node-positive invasive ductal carcinoma following combination hormone replacement therapy cessation: a case report
Translational Breast Cancer Research
2022;
3:
29
(30 July 2022)
Case Report
Metastatic breast cancer in a transgender female with history of mantle field radiation and free silicone breast injections: case report
Translational Breast Cancer Research
2022;
3:
28
(30 July 2022)
Case Report
A case report of gender-affirming mastectomy in a transgender individual with breast cancer
Translational Breast Cancer Research
2022;
3:
27
(30 July 2022)
Review Article
Thoughts on therapy strategy in the era of “after anti-HER2 TKI” in CSCO BC Guidelines 2022
Translational Breast Cancer Research
2022;
3:
26
(30 July 2022)
Review Article
Key points of breast cancer management under public health emergencies
Translational Breast Cancer Research
2022;
3:
25
(30 July 2022)
Original Article
A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer, residual disease in breast and nodes combined with Ki-67 (RDBN-K)
Translational Breast Cancer Research
2022;
3:
24
(30 July 2022)
Original Article
Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes
Translational Breast Cancer Research
2022;
3:
23
(30 July 2022)
Consensus
CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis
Translational Breast Cancer Research
2022;
3:
22
(30 July 2022)
Editorial
Comments to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022
Translational Breast Cancer Research
2022;
3:
21
(30 July 2022)
Editorial Commentary
New progress in early breast cancer treatment in 2021
Translational Breast Cancer Research
2022;
3:
20
(30 April 2022)
Case Report
Pseudoangiomatous stromal hyperplasia causing massive unilateral breast enlargement—a case report
Translational Breast Cancer Research
2022;
3:
19
(30 April 2022)
Review Article
Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates
Translational Breast Cancer Research
2022;
3:
18
(30 April 2022)
Review Article
Narrative review of current status and recommendations in treatment for advanced triple-negative breast cancer
Translational Breast Cancer Research
2022;
3:
17
(30 April 2022)
Review Article
Narrative review of progress in pathological diagnosis of breast cancer
Translational Breast Cancer Research
2022;
3:
16
(30 April 2022)
Original Article
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study
Translational Breast Cancer Research
2022;
3:
15
(30 April 2022)
Original Article
The study of correlation between nomogram prediction of uric acid and different chemotherapy regimens in breast cancer patients
Translational Breast Cancer Research
2022;
3:
14
(30 April 2022)
Guideline
Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
Translational Breast Cancer Research
2022;
3:
13
(30 April 2022)
Editorial
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guideline update: adjuvant therapy for triple negative breast cancer in 2022
Translational Breast Cancer Research
2022;
3:
12
(30 April 2022)
Editorial
Escalating and de-escalating treatments in HR+HER2− early-stage breast cancer
Translational Breast Cancer Research
2022;
3:
11
(30 April 2022)
Editorial
CDK4/6 inhibitors combined with fulvestrant for HR+/HER2− advanced breast cancer
Translational Breast Cancer Research
2022;
3:
10
(30 April 2022)
Case Report
A fatal case of pneumonitis and hypogammaglobulinemia with use of a CDK4/6 inhibitor in metastatic breast cancer: case report
Translational Breast Cancer Research
2022;
3:
9
(31 January 2022)
Original Article
Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis
Translational Breast Cancer Research
2022;
3:
8
(31 January 2022)
Editorial Commentary
Monarch plus: a research review
Translational Breast Cancer Research
2022;
3:
7
(31 January 2022)
Editorial Commentary
Endocrine therapy leads the first- and second-line treatment options for hormone receptor-positive advanced breast cancer—comments on the Monarch plus study
Translational Breast Cancer Research
2022;
3:
6
(31 January 2022)
Editorial Commentary
MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunities
Translational Breast Cancer Research
2022;
3:
5
(31 January 2022)